Guerrieri Mario, Wong Kevin, Ryan Gail, Millward Michael, Quong George, Ball David L
Division of Radiation Oncology, Besen Family Department of Radiation, Peter MacCallum Cancer Centre, St. Andrews Place, Locked Bag 1, A'Beckett Street, East Melbourne, Victoria 8006, Australia.
Lung Cancer. 2004 Oct;46(1):107-11. doi: 10.1016/j.lungcan.2004.02.019.
To determine if the addition of carboplatin chemotherapy to whole brain irradiation improves response and survival in patients with brain metastases from non-small cell lung cancer (NSCLC).
Forty-two patients with brain metastases from NSCLC and performance status ECOG 0-2 were randomised to receive either whole brain radiotherapy (WBRT) alone (20Gy in five fractions) or the same radiotherapy plus concomitant carboplatin (70 mg/m(2) intravenously for 5 days).
The median survival was 4.4 months in the radiotherapy alone (RT) arm and 3.7 months in the combined treatment (RTC) arm (P = 0.64). The objective response rates of 10% on the RT arm and 29% on the RTC arm were not significantly different (P = 0.24). The trial was closed early because of poor accrual.
Although no firm conclusions can be made regarding the efficacy of the combined treatment, this prospective study highlights the poor objective response rates and relatively poor symptom control despite standard treatment of brain metastases from NSCLC.
确定在全脑放疗基础上加用卡铂化疗是否能提高非小细胞肺癌（NSCLC）脑转移患者的缓解率和生存率。
42例NSCLC脑转移且美国东部肿瘤协作组（ECOG）体能状态为0 - 2级的患者被随机分为两组，一组仅接受全脑放疗（WBRT）（20Gy分5次照射），另一组接受相同放疗并同时加用卡铂（70mg/m²静脉滴注，共5天）。
单纯放疗（RT）组的中位生存期为4.4个月，联合治疗（RTC）组为3.7个月（P = 0.64）。RT组的客观缓解率为10%，RTC组为29%，差异无统计学意义（P = 0.24）。由于入组情况不佳，该试验提前结束。
尽管对于联合治疗的疗效无法得出确切结论，但这项前瞻性研究凸显了NSCLC脑转移患者在接受标准治疗后客观缓解率较低且症状控制相对较差的情况。
